This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. is seeing a significant drop in its stock performance as investors respond to current market conditions.
Helix BioPharma Corp. (HBP.TO) is having a tough day in the market, with its stock price falling by 4.20% to CA$1.37. This decline reflects ongoing concerns among investors about the company's financial health and future outlook.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$151.99M
52W high
$5.40
52W low
$1.10
1W change
-3.00%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 28.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+28.9% Upside
Current Price
C$1.94
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
40.0%
Annualized
90-Day Vol
58.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.06 | C$1.79 – C$2.36 |
| 60 trading days | C$2.19 | C$1.80 – C$2.66 |
| 90 trading days | C$2.32 | C$1.83 – C$2.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious about Helix BioPharma's stock, especially given its recent performance and the absence of significant news to support a recovery.
Stock Down 4.20%
Helix BioPharma's market cap is now CA$106.93 million, indicating skepticism from investors.
Bull case
If Helix BioPharma can successfully advance its pipeline candidates, particularly the Tumor Defense Breaker™ L-DOS47, there could be potential for growth and a rebound in stock value.
Bear case
Without strong financial results or strategic partnerships, Helix BioPharma may continue to face challenges, which could lead to further declines in its stock price.
Market Performance Overview
Advertisement
Helix BioPharma Corp. experienced a 4.20% drop in its stock during today’s trading session, closing at CA$1.37. This decline reflects the general market sentiment towards small-cap biotech firms, especially those with limited financial updates.
Investor Sentiment and Future Outlook
With no recent significant news to boost investor confidence, Helix BioPharma's stock performance highlights ongoing worries about its financial viability. Investors should monitor upcoming financial results and strategic developments to assess the potential for recovery.
Understanding the Market Dynamics
The drop in Helix BioPharma's stock today emphasizes the volatility often seen in the biotech sector. The company's efforts to advance its therapeutic candidates are critical, but without solid financial backing and market support, the stock may continue to face difficulties.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
